SUCCESSFUL DEVELOPMENT OF A NEW PRODUCT BY MEDITOP PHARMACEUTICAL LTD.
A new generic antiepileptic drug developed by MEDITOP Pharmaceuticals Ltd. has been successfully registered under the DCP in six countries of the European Union (Hungary, Germany, Spain, Portugal, Italy, France).
The active substance for the treatment of epilepsy has not been available to patients in Hungary so far, and this product offers a new opportunity for treating physicians.
MEDITOP Pharmaceuticals Ltd. has developed a pharmaceutical technology process for the production of the product which does not infringe the process protected by the original manufacturer and, thanks to its novelty, has been granted European patent protection.